Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2015—Verax Biomedical has gained FDA clearance to expand the use of its Verax Platelet PGD test—a rapid test for the detection of bacterial contamination in platelets intended for transfusion. The test is an immunoassay used on the day of transfusion at the point of care, a hospital or transfusion service, to quickly detect bacterial contamination in platelets and protect patients from receiving contaminated transfusions.
July 2015—Halozyme Therapeutics and Ventana Medical Systems announced a global agreement to collaborate on the development of a companion diagnostic assay for use with Halozyme’s investigational new drug, PEGPH20, which Ventana would ultimately commercialize.
July 2015—Seegene announced that its Allplex Gastrointestinal Full Panel Assay has received the CE-IVD mark, enabling marketing in Europe and certain other countries.
July 2015—Bio SB announced a line of rabbit monoclonal antibodies, PD-L1/CD274, for immunohistochemistry with extensive protein immunogenicity analysis of targeted epitopes, high sensitivity specificity, and low background noise.
July 2015—Beckman Coulter Diagnostics announced the publication of research results in Clinical Biochemistry (Storrow AB, et al. 2015;48:254–259; 260–267) that identify the precise magnitude of change in cardiac troponin required for early diagnosis of a heart attack using its Access AccuTnI+3 troponin I blood test. Beckman’s troponin-I assay has been clinically proven through a large, multicenter study and is FDA-cleared and directly aligned with the FDA’s October 2010 guidance to manufacturers of troponin tests.
July 2015—Thermo Fisher introduced the Thermo Scientific Orbitrap Fusion Lumos Tribrid Mass Spectrometer, the newest addition to its line of Orbitrap Tribrid mass spectrometers. Designed to expand researchers’ capabilities in advanced proteomics and metabolomics applications, including targeted, data-independent acquisition and top-down analyses, the Orbitrap Fusion Lumos Tribrid has a high level of sensitivity, delivering complete protein sequence coverage and allowing scientists to perform more inclusive analyses.
July 2015—Streck’s Calibration Verification Assessment (CVA) is now assayed for the Horiba ABX Micros 60 instrument. CVA is an assayed linearity control kit used to determine the patient reportable range of three-part and five-part hematology instruments.
July 2015—MDxHealth revealed data with the aim of demonstrating the prognostic value of its ConfirmMDx for Prostate Cancer test. The data, offered in two presentations at the American Urology Association’s annual meeting in May, show the test’s ability to identify patients likely to harbor clinically significant prostate cancer from negative biopsy tissue.
July 2015—Pathology Associates Medical Laboratories has entered into a collaborative agreement with Axela to develop multiplex assays focused on immune status for vaccine preventable diseases.
July 2015—Corgenix Medical has received U.S. FDA emergency use authorization for its ReEBOV Antigen Rapid Test. The test is to be used for the presumptive detection of Ebola Zaire virus in individuals with signs and symptoms of Ebola virus infection in conjunction with epidemiological risk factors, including geographic locations with high prevalence of Ebola infection.
